Active — Not RecruitingPhase 4

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

Denmark5,000 participantsStarted 2023-04-01

Plain-language summary

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in venous thromboembolism across Danish hospitals.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * A diagnosis of VTE in outpatient clinic or as discharge diagnosis after hospitalization. * A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit. Exclusion Criteria: * A prescription of a NOAC within 90 days prior to hospitalization or outpatient clinic visit for VTE. * Patients with NOAC preference apart from preference consistent with current cluster randomized NOAC. * Other contraindications mentioned in the "Summary of Product Characteristics" for the respective NOAC.

What they're measuring

Primary efficacy outcome: a composite endpoint of new venous thromboembolism or all-cause death.

Timeframe: 6 months.

Trial details

NCT IDNCT03129555

SponsorHerlev and Gentofte Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-03-31

View on ClinicalTrials.gov More Deep Vein Thrombosis trials